Gut Microbiome Alterations Following Oral Serum-Derived Bovine Immunoglobulin Administration in the Management of Dysbiosis

Overview

Journal Cureus

Date 2025 Jan 17

PMID 39822451

Authors

Sabine Hazan

Guanhui Bao

Adriana Vidal

Adonis Sfera

Affiliations

Soon will be listed here.

Abstract

Introduction: Inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) are chronic disorders of the gastrointestinal tract associated with gut microbiota dysbiosis and inflammation. Serum-derived bovine immunoglobulin (SBI) is used to manage IBS and IBD and has shown prebiotic-like effects in ex vivo models. Re-establishing a healthy gut microbiome with novel treatments like SBI could help treat the underlying causes of these diseases leading to higher and sustained patient response. The objective of this study was to assess whether supplementation with SBI would improve dysbiosis in IBD and IBS patients.

Methods: This cross-sectional, single-site study had each participant serving as their own control. Stool samples from 18 patients with either IBS or IBD were analyzed before and after SBI administration. The relative abundance of bacterial diversity was assessed using metagenomic next-generation sequencing-based profiling.

Results: Species diversity statistically significantly increased for measures of richness (Shannon index) (p < 0.0082) and evenness (Gini-Simpson index) (p < 0.0017). Phylum-level changes showed a 2.7-fold increase in (p = 0.0181), 0.66-fold decrease in (p = 0.0401), and 0.38-fold decrease in (p = 0.0071) after treatment with SBI. At the genus level, the relative abundances showed decreased (p = 0.0121) and decreased (p = 0.0108) as well as increased (p = 0.0204), compared to pre-treatment levels. At the genus level, a 1.8-fold increase of (p = 0.0225) occurred upon treatment with SBI.

Conclusion: These findings confirm the prebiotic effects of SBI and suggest an additional mechanism of action in managing IBD and IBS symptoms. SBI re-establishes homeostasis in patients with IBD and IBS by decreasing and increasing and species diversity. These insights highlight the promise of new therapeutic strategies for managing IBS and IBD by targeting dysbiosis and underscore the potential of personalized treatments based on a patient's gut microbiome profile.

References

McSharry K, Dalzell A, Leiper K, El-Matary W . Systematic review: the role of tacrolimus in the management of Crohn's disease. Aliment Pharmacol Ther. 2011; 34(11-12):1282-94. DOI: 10.1111/j.1365-2036.2011.04873.x. View

Pittayanon R, Lau J, Yuan Y, Leontiadis G, Tse F, Surette M . Gut Microbiota in Patients With Irritable Bowel Syndrome-A Systematic Review. Gastroenterology. 2019; 157(1):97-108. DOI: 10.1053/j.gastro.2019.03.049. View

Van den Abbeele P, Kunkler C, Poppe J, Rose A, van Hengel I, Baudot A . Serum-Derived Bovine Immunoglobulin Promotes Barrier Integrity and Lowers Inflammation for 24 Human Adults Ex Vivo. Nutrients. 2024; 16(11). PMC: 11174680. DOI: 10.3390/nu16111585. View

Ben-Horin S, Kopylov U, Chowers Y . Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev. 2013; 13(1):24-30. DOI: 10.1016/j.autrev.2013.06.002. View

Hazan S, Stollman N, Bozkurt H, Dave S, Papoutsis A, Daniels J . Lost microbes of COVID-19: , depletion and decreased microbiome diversity associated with SARS-CoV-2 infection severity. BMJ Open Gastroenterol. 2022; 9(1). PMC: 9051551. DOI: 10.1136/bmjgast-2022-000871. View

Sakurai T, Odamaki T, Xiao J . Production of Indole-3-Lactic Acid by Strains Isolated fromHuman Infants. Microorganisms. 2019; 7(9). PMC: 6780619. DOI: 10.3390/microorganisms7090340. View

David L, Maurice C, Carmody R, Gootenberg D, Button J, Wolfe B . Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2013; 505(7484):559-63. PMC: 3957428. DOI: 10.1038/nature12820. View

Shen J, Yang L, You K, Chen T, Su Z, Cui Z . Indole-3-Acetic Acid Alters Intestinal Microbiota and Alleviates Ankylosing Spondylitis in Mice. Front Immunol. 2022; 13:762580. PMC: 8854167. DOI: 10.3389/fimmu.2022.762580. View

Fakhoury M, Negrulj R, Mooranian A, Al-Salami H . Inflammatory bowel disease: clinical aspects and treatments. J Inflamm Res. 2014; 7:113-20. PMC: 4106026. DOI: 10.2147/JIR.S65979. View

10.

Shan Y, Lee M, Chang E . The Gut Microbiome and Inflammatory Bowel Diseases. Annu Rev Med. 2021; 73:455-468. PMC: 10012812. DOI: 10.1146/annurev-med-042320-021020. View

11.

Shafran I, Burgunder P, Wei D, Young H, Klein G, Burnett B . Management of inflammatory bowel disease with oral serum-derived bovine immunoglobulin. Therap Adv Gastroenterol. 2015; 8(6):331-9. PMC: 4622288. DOI: 10.1177/1756283X15593693. View

12.

Wilson D, Evans M, Weaver E, Shaw A, Klein G . Evaluation of serum-derived bovine immunoglobulin protein isolate in subjects with diarrhea-predominant irritable bowel syndrome. Clin Med Insights Gastroenterol. 2014; 6:49-60. PMC: 4020402. DOI: 10.4137/CGast.S13200. View

13.

Petschow B, Blikslager A, Weaver E, Campbell J, Polo J, Shaw A . Bovine immunoglobulin protein isolates for the nutritional management of enteropathy. World J Gastroenterol. 2014; 20(33):11713-26. PMC: 4155361. DOI: 10.3748/wjg.v20.i33.11713. View

14.

Petschow B, Burnett B, Shaw A, Weaver E, Klein G . Dietary requirement for serum-derived bovine immunoglobulins in the clinical management of patients with enteropathy. Dig Dis Sci. 2014; 60(1):13-23. PMC: 4284400. DOI: 10.1007/s10620-014-3322-0. View

15.

Menees S, Maneerattannaporn M, Kim H, Chey W . The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2011; 107(1):28-35. DOI: 10.1038/ajg.2011.355. View

16.

Saha L . Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine. World J Gastroenterol. 2014; 20(22):6759-73. PMC: 4051916. DOI: 10.3748/wjg.v20.i22.6759. View

17.

Khan I, Ullah N, Zha L, Bai Y, Khan A, Zhao T . Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome. Pathogens. 2019; 8(3). PMC: 6789542. DOI: 10.3390/pathogens8030126. View

18.

Camilleri M . Diagnosis and Treatment of Irritable Bowel Syndrome: A Review. JAMA. 2021; 325(9):865-877. DOI: 10.1001/jama.2020.22532. View

19.

Roager H, Licht T . Microbial tryptophan catabolites in health and disease. Nat Commun. 2018; 9(1):3294. PMC: 6098093. DOI: 10.1038/s41467-018-05470-4. View

20.

Lee M, Chang E . Inflammatory Bowel Diseases (IBD) and the Microbiome-Searching the Crime Scene for Clues. Gastroenterology. 2020; 160(2):524-537. PMC: 8098834. DOI: 10.1053/j.gastro.2020.09.056. View